Drugs / XEN-D0501
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT03278158 | Sep 2017 → Nov 2018 | type 2 diabetes mellitus | Pila Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02233699 | Jul 2014 → May 2015 | — | Xention Ltd | Completed | No outcome recorded |
| Phase 2 | NCT02233686 | Feb 2014 → Feb 2015 | chronic obstructive pulmonary disease | Xention Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05353686 Comparator | Feb → Dec 2019 | type 2 diabetes mellitus | Pila Pharma | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XEN-D0501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05353686 ↗ |
| Action | Inhibit | “XEN-D0501, a Transient Receptor Potential Vanilloid Receptor 1 (TRPV1) Antagonist” NCT02233699 ↗1“Vanilloid receptor antagonist” CHEMBL3707293 ↗ |
| Route | Oral | “Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet” NCT03278158 ↗ |
| Target | TRPV1 | “Vanilloid receptor antagonist” CHEMBL3707293 ↗ |